# BioMarin Pharmaceutical Inc (BMRN) · Edgar & Edgarette company card

> BioMarin Pharmaceutical (BMRN) grew revenue 12.9% in FY2025 to $3.2 billion, operating margin 12.7% against a -3.8% median for pharmaceutical preparations, equity 80.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1048477 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/BMRN) · [JSON](https://www.pops4.com/boards/company/BMRN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $3.2B |
| Revenue growth, 1 year | 12.9% |
| Revenue growth per year | 14.9% |
| Operating margin | 12.7% (prior year 17.0%) |
| Net margin | 10.8% |
| Operating cash flow | $828M |
| Capital spending | $103M |
| Free cash flow | $725M |
| Cash | $1.3B |
| Long-term debt | — |
| Total assets | $7.6B |
| Total equity | $6.1B |
| Equity ÷ assets | 80.2% |
| Return on equity | 5.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 7.43 (safe zone)
- Piotroski F: 6 of 9 (solid)
- Beneish M: -2.52 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $3.2B (FY2025). Experience: revenue up 12.9% on the year, up 14.9% a year over 4 years; operating margin 12.7%, down from 17.0%. Soundness: equity 80.2% of assets, return on equity 5.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $3.3B and $3.9B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $3.1B to $4.2B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 12.7% against a -3.8% median; growth 12.9% against 13.7%.

Range logged 2026-09-29, receipt 7a9e52d25b04f6a3, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-09-14 ([filing](https://www.sec.gov/Archives/edgar/data/1048477/000162828026061717/0001628280-26-061717-index.htm))

## Recent filings

- 10-Q · filed 2026-11-03 · [filing](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000023/0001048477-26-000023-index.htm)
- 8-K · filed 2026-11-02 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000021/0001048477-26-000021-index.htm)
- 8-K · filed 2026-10-06 · 2.02 Results of Operations and Financial Condition · [filing](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000019/0001048477-26-000019-index.htm)
- 8-K · filed 2026-09-30 · 1.01 Entry into a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/1048477/000162828026063981/0001628280-26-063981-index.htm)
- 8-K · filed 2026-09-15 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1048477/000162828026061973/0001628280-26-061973-index.htm)
- 8-K · filed 2026-09-14 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1048477/000162828026061717/0001628280-26-061717-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001048477.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1048477

## Cite

POPS4, Edgar & Edgarette: BioMarin Pharmaceutical Inc (BMRN) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/BMRN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.